A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. - Wikidata - wikimedia - TriplyDB

A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma.

A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q37588583

about

Thyroid lymphoma: recent advances in diagnosis and optimal management strategies Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis.Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?Follow-up of patients receiving rituximab for diffuse large B cell lymphoma: an overview of systematic reviews.Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study.Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands.A Case of Rituximab-Induced Necrotizing Fasciitis and a Review of the Literature.Rituximab biosimilar evaluated by network meta-analysis.Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data

P2860

Q26827420-E5EBB4B3-F43C-44E4-AEA6-F4AD39E6291D Q30500238-BF451CBA-BE37-420C-8B98-C3D38C56D3B3 Q33421964-86637509-90AA-4DEE-8385-F25B8861C886 Q34757945-C24EC6B3-93FC-4D7C-B69F-876FE850EAF3 Q34763541-3DD3D69A-5BDE-4800-9DB9-BA78F34961D3 Q34815753-DF16739D-0846-4AEF-B539-56333C4A44AC Q37552047-9B95A7AC-86FE-4C81-957C-919B7A8DF821 Q42706755-9B047484-AE78-44E8-8D74-F5A696225258 Q47151262-359A4C8B-4AF0-4AFC-8A75-6C7E402BD9E9 Q47409813-CB80DAD2-0D28-4657-A5E1-044EA6C6C4E4 Q53161291-F197F225-5354-4400-B7D2-0A4AE55AF68B Q58908211-D618ACC0-C9CD-4958-B2FA-F812A0E26DA7

P2860

A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q37588583

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A systematic review and meta-a ...... B-cell non-Hodgkin's lymphoma.

@en

A systematic review and meta-a ...... B-cell non-Hodgkin's lymphoma.

@nl

type

label

A systematic review and meta-a ...... B-cell non-Hodgkin's lymphoma.

@en

A systematic review and meta-a ...... B-cell non-Hodgkin's lymphoma.

@nl

prefLabel

A systematic review and meta-a ...... B-cell non-Hodgkin's lymphoma.

@en

A systematic review and meta-a ...... B-cell non-Hodgkin's lymphoma.

@nl

P1433

Q37588583-395C6790-1F3B-4DD0-8AED-FDD327367B4A

P1476

Q37588583-F0EB91E3-ABCA-4EB7-9BBD-989A9370CE59

P2093

Q37588583-218B0682-FF60-4903-9D7D-9BB93805A475

Q37588583-4C059FE8-18C9-4FAD-9535-6D3F768381FD

Q37588583-4DB38876-E3BC-4E26-AD02-09B31C80D89A

Q37588583-93207F28-0FF1-4C1B-A7E6-99E6F1BBBDF6

Q37588583-9B2EBADD-A0CD-4C28-A23A-143BA548FC9D

Q37588583-A9886B6C-5D4A-411B-9CCF-2050F160ED55

Q37588583-D901982C-2659-4B2E-91BA-3A750ABCC217

P2860

Q37588583-0B857B77-7F0D-4A70-B776-08E304B30FC2

Q37588583-107C07A2-258E-481B-A716-0F0CE9B1A0CE

Q37588583-12930F58-1DF5-4B3A-8295-D62155754542

Q37588583-20E96AC6-EDB5-4126-B5B6-FF6EC109866B

Q37588583-3271AC17-0A90-4C26-A2DD-345A32AAFC29

Q37588583-40E9E3F4-9798-4132-B978-3A85A038B020

Q37588583-41B616BA-056B-4A12-B610-BAD201DE5E58

Q37588583-4987C0DA-7299-4468-A962-9EA518140828

Q37588583-531AD1D8-3B21-4CEC-BC62-EAE763BF2525

Q37588583-546CD70B-9A11-4251-B6C4-86C84FC3D7FA

P304

Q37588583-9440BFD9-DF98-4F46-A0FB-079C66D4E445

P31

Q37588583-051F169C-3975-461D-AE5D-FAD91AE2D15E

Q37588583-72ce49b0-2d3e-4fb0-bfd7-331b0fbb7750

P356

Q37588583-5217E3DE-F667-40EB-B106-91E3A551C12C

P433

Q37588583-1A52B800-3B27-4516-984D-9E91D6BFCAA6

P478

Q37588583-2E432771-1F51-441D-9F7B-E4AF0A654215

P577

Q37588583-99FD42A5-3078-4B03-8697-48A015C01273

P5875

Q37588583-4F163A05-01AD-4A17-995B-5ABCBE1DC653

P698

Q37588583-5CBBE24F-6C19-4CBE-859E-8BE37A4FB737

P921

Q37588583-A04720FC-9575-4837-A14B-460B60DF2751

P356

02841860903150502

P1433

Acta Oncologica

P1476

A systematic review and meta-a ...... B-cell non-Hodgkin's lymphoma.

@en

P2093

Guanghui Gao

http://www.w3.org/2001/XMLSchema#string

Jingwei Jiang

http://www.w3.org/2001/XMLSchema#string

Qiong Zhan

http://www.w3.org/2001/XMLSchema#string

Ruofan Huang

http://www.w3.org/2001/XMLSchema#string

Xiaohua Liang

http://www.w3.org/2001/XMLSchema#string

Xinli Zhou

http://www.w3.org/2001/XMLSchema#string

Zhaohui Chu

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Cancer statistics, 2008

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.

Identifying relevant studies for systematic reviews

P304

3-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/02841860903150502

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26774345

http://www.w3.org/2001/XMLSchema#string

P698

19714523

http://www.w3.org/2001/XMLSchema#string

P921